Jakavi wins improved IQWiG verdict but loses orphan status
This article was originally published in Scrip
Executive Summary
Novartis's Jakavi (ruxolitinib) has won a verdict of considerable added benefit from Germany's health technology appraisal body, IQWiG, an improvement on its previous verdict of minor added benefit. Novartis had to submit to a reassessment once Jakavi surpassed the maximum sales threshold to qualify as an orphan drug under German rules.